Next Article in Journal
E-Manuscript Article Summaries *
Previous Article in Journal
A Call for Action in Survivorship Research and Care
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 1
10.3747/co.19.959
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Letter

Re. Karam I, Melosky B. Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions

by
Vera Hirsh
Medical Oncology Department, MUHC Royal Victoria Hospital, 687 Pine Avenue West, Suite A3.04, Montreal, QC H3A 1A1, Canada
Curr. Oncol. 2012, 19(1), 21-22; https://doi.org/10.3747/co.19.959
Submission received: 3 November 2011 / Revised: 8 December 2011 / Accepted: 12 January 2012 / Published: 1 February 2012

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

I agree with the statement in this publication that tyrosine kinase inhibitors (tkis) against the epidermal growth factor receptor (egfr) should be considered [...]

Share and Cite

MDPI and ACS Style

Hirsh, V. Re. Karam I, Melosky B. Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions. Curr. Oncol. 2012, 19, 21-22. https://doi.org/10.3747/co.19.959

AMA Style

Hirsh V. Re. Karam I, Melosky B. Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions. Current Oncology. 2012; 19(1):21-22. https://doi.org/10.3747/co.19.959

Chicago/Turabian Style

Hirsh, Vera. 2012. "Re. Karam I, Melosky B. Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions" Current Oncology 19, no. 1: 21-22. https://doi.org/10.3747/co.19.959

Article Metrics

Back to TopTop